ArticleApplied microbiology and biotechnology2021
Gut microbiota profiles and characterization of cultivable fungal isolates in IBS patients.
Article in Applied microbiology and biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- Pooled it
- Effects of remote ischemic preconditioning on postoperative gastrointestinal function in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled trial.BMC anesthesiology · 2026Trial
- Otilonium bromide exhibits novel antifungal activity againstVirulence · 2026Article
- Integrating host-microbiome multi-omics with machine learning: methods, benchmarks, and translational applications.Science China. Life sciences · 2026Review
- Gut Microbial Dysbiosis and Male Reproductive Health: Current Insights and Future Directions.International journal of molecular sciences · 2026Review
- Abdominal Pain After Bariatric Surgery and the Role of the Gut: A Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Review
- The Interplay Between Immunological Status and Gut Microbial Dysbiosis in the Development of the Symptoms of Irritable Bowel Syndrome: A Systematic Review with Meta-Analysis.Digestive diseases and sciences · 2026Review
- Therapeutic potential ofMicrobiome research reports · 2026Article
- The pathogenicity and future treatment strategies ofFrontiers in cellular and infection microbiology · 2026Review
- Low-Grade Inflammation: Pathophysiological Mechanisms and Drug Targets in Irritable Bowel Syndrome with Diarrhea.Journal of inflammation research · 2026Review
- Multi-omics analysis reveals the pathobiome-host interactions in the bleaching disease of the seaweed Saccharina japonica.Microbiome · 2025Article
- Comparative analysis of gut microbiota in free range and house fed yaks from Linzhou County.Scientific reports · 2025Article
- The Gut Mycobiome for Precision Medicine.Journal of fungi (Basel, Switzerland) · 2025Review
- Lacidophilin tablets relieve irritable bowel syndrome in rats by regulating gut microbiota dysbiosis and intestinal inflammation.Scientific reports · 2025Article
- Typing of feces-derived Candida albicans strains using a novel seven-locus microsatellite panel reveals associations with yeast phenotype in individuals with inflammatory bowel disease.Pathogens and disease · 2025Article
- GABA-producingMicrobiome research reports · 2025Article
- Energy metabolism and the intestinal barrier: implications for understanding and managing intestinal diseases.Frontiers in microbiology · 2025Review
- A preliminary study of the association betweenFrontiers in medicine · 2025Article
- The Role of Gut Microbiome in Irritable Bowel Syndrome: Implications for Clinical Therapeutics.Biomolecules · 2024Review
- Characterization of Yeast Isolated from the Gut Microbiota of Tunisian Children with Autism Spectrum Disorder.Journal of fungi (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
Abstract
Studies so far conducted on irritable bowel syndrome (IBS) have been focused mainly on the role of gut bacterial dysbiosis in modulating the intestinal permeability, inflammation, and motility, with consequences on the quality of life. Limited evidences showed a potential involvement of gut fungal communities. Here, the gut bacterial and fungal microbiota of a cohort of IBS patients have been characterized and compared with that of healthy subjects (HS). The IBS microbial community structure differed significantly compared to HS. In particular, we observed an enrichment of bacterial taxa involved in gut inflammation, such as Enterobacteriaceae, Streptococcus, Fusobacteria, Gemella, and Rothia, as well as depletion of health-promoting bacterial genera, such as Roseburia and Faecalibacterium. Gut microbial profiles in IBS patients differed also in accordance with constipation. Sequence analysis of the gut mycobiota showed enrichment of Saccharomycetes in IBS. Culturomics analysis of fungal isolates from feces showed enrichment of Candida spp. displaying from IBS a clonal expansion and a distinct genotypic profiles and different phenotypical features when compared to HS of Candida albicans isolates. Alongside the well-characterized gut bacterial dysbiosis in IBS, this study shed light on a yet poorly explored fungal component of the intestinal ecosystem, the gut mycobiota. Our results showed a differential fungal community in IBS compared to HS, suggesting potential for new insights on the involvement of the gut mycobiota in IBS. KEY POINTS: • Comparison of gut microbiota and mycobiota between IBS and healthy subjects • Investigation of cultivable fungi in IBS and healthy subjects • Candida albicans isolates result more virulent in IBS subjects compared to healthy subjects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.